Drug Profile


Alternative Names: AE 0047; Calbren; GJ 0956; Vatanidipine

Latest Information Update: 11 Jul 2002

Price : $50

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Class Antihyperlipidaemics; Antihypertensives; Neuroprotectants
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Hypertension; Stroke

Most Recent Events

  • 31 Jan 2002 Discontinued - Preclinical for Atherosclerosis in Japan (unspecified route)
  • 31 Jan 2002 Discontinued - Preregistration for Hypertension in Japan (unspecified route)
  • 01 Oct 2001 Welfide Corporation merged with Mitsubishi-Tokyo Pharmaceuticals to form Mitsubishi Pharma Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top